Penna C, Mognetti B, Tullio F, Gattullo D, Mancardi D, Pagliaro P, Alloatti G
Laboratories of Physiology, Department of Clinical and Biological Sciences, University of Turin, Italy.
J Physiol Pharmacol. 2008 Mar;59(1):47-54.
Endogenous platelet activating factor (PAF) is involved in heart ischemic preconditioning. PAF can also afford pharmacological preconditioning. We studied whether mitochondrial-ATP-sensitive K(+) (mK(ATP)) channels and reactive oxygen species (ROS) are involved in PAF-induced cardioprotection. In Group 1 control hearts, Langendorff-perfused rat hearts underwent 30 min ischemia and 2 hours of reperfusion. Group 2 hearts, before ischemia, were perfused for 19 min with PAF (2x10(-11) M); Groups 3 and 4 hearts were co-infused with PAF and N-acetyl-L-cysteine or 5-hydroxydecanoate to scavenge ROS or to block mK(ATP) channels, respectively. Left ventricular pressure and infarct size were determined. PAF-pretreatment reduced infarct size (33 +/- 4% vs 64 +/- 4.6 % of the area at risk of control hearts) and improved pressure recovery. Infarct-sparing effect of PAF was abolished by N-acetyl-L-cysteine and 5-hydroxydecanoate. Thus, the cardioprotective effect exerted by PAF-pretreatment involves activation of mK(ATP) channels and redox signaling in pre-ischemic phase.
内源性血小板活化因子(PAF)参与心脏缺血预处理。PAF也能提供药物预处理。我们研究了线粒体ATP敏感性钾(mK(ATP))通道和活性氧(ROS)是否参与PAF诱导的心脏保护作用。在第1组对照心脏中,采用Langendorff灌注法对大鼠心脏进行30分钟缺血和2小时再灌注。第2组心脏在缺血前用PAF(2×10(-11)M)灌注19分钟;第3组和第4组心脏分别与PAF和N-乙酰-L-半胱氨酸或5-羟基癸酸共同灌注,以清除ROS或阻断mK(ATP)通道。测定左心室压力和梗死面积。PAF预处理可减小梗死面积(与对照心脏危险区域面积的比例分别为33±4%和64±4.6%)并改善压力恢复。N-乙酰-L-半胱氨酸和5-羟基癸酸消除了PAF的梗死保护作用。因此,PAF预处理所发挥的心脏保护作用涉及缺血前期mK(ATP)通道的激活和氧化还原信号传导。